



## Drug Formulary Update, January 2020 State Programs

Updates to the HealthPartners State Programs are listed below.

Please see [www.healthpartners.com/formularies](http://www.healthpartners.com/formularies) for details.

All updates are effective January 1 2020 unless otherwise noted.

Drug name	Current Status	New Status	Comments
Alirocumab (Praluent)	NF-PA, SP	NF-PA	DHS non-preferred product
Azithromycin (Azasite)	F	NF	DHS non-preferred product
Blood factor products	F, SP	F-PA, SP	Includes Advate, Adynovate, Afstyla, Eloctate, Humate, Jivi, Nuwiiq, Xyntha
Darolutamide (Nubeqa)	NF-PA, SP, Oncology	F-PA, SP, Oncology	
Econazole cream	NF	F-QL	
Entrectinib (Rozlytrek)	NF-PA, SP, Oncology	F-PA, SP, Oncology	
Evolocumab (Repatha)	F-PA, SP	F-PA	DHS non-preferred product
Fedratinib (Inrebic)	NF-PA, SP, Oncology	F-PA, SP, Oncology	
Glucagon (Baqsimi)	NF	F	
Glucagon (Gvoke)	NF	F	
Lefamulin (Xenleta)	NF	F-PA-QL	
Norethindrone/ ethinyl estradiol (Blisovi)	NF-PA	F	
Pexidartinib (Turalio)	NF-PA, SP, Oncology	F-PA, SP, Oncology	
Pyridostigmine ER	F	F-PA	
Quantity limits			Several quantity limits added, per FDA-maximum dosing
Ramelteon	F	F-PA	DHS non-preferred product
Risedronate	F-PA	NF-PA	DHS non-preferred product
Selinexor (Xpovio)	NF, Oncology	F-PA, SP, Oncology	
Solriamfetol (Sunosi)	NF-PA	F-PA-QL	
Tafamidis (Vyndamax)	NF-PA, SP	F-PA, SP	

Formulary Abbreviations: F = Formulary, NF = Non-Formulary, PA = Prior Authorization,  
SP = Specialty Drug, QL = Quantity Limit, Oncology = Oncology Program  
DHS:

State Programs Formulary Update, page 2 of 2

Drug name	Current Status	New Status	Comments
Triamcinolone nasal	NF	F	
Upadacitinib (Rinvoq)	NF-PA, SP	F-PA-QL, SP	Added Nov 11 2019

Formulary Abbreviations: F = Formulary, NF = Non-Formulary, PA = Prior Authorization, ST = Step Therapy, SP = Specialty Drug, QL = Quantity Limit, AE = Age Edit, TD = Trial Drug Program